

USE OF 2 α -METHYL-19-NOR-20(S)-1 α ,25-DIHYDROXYVITAMIN D₃
TO INCREASE BONE STRENGTH

ABSTRACT OF THE DISCLOSURE

5 This invention provides pharmaceutical uses for 2 α -methyl-19-nor-20(S)-
1 α ,25-dihydroxyvitamin D₃. This compound is characterized by high bone
calcium mobilization activity demonstrating preferential activity on bone. This
results in a novel therapeutic agent for the treatment of diseases where bone
formation is desired, particularly osteoporosis. This compound also exhibits
10 pronounced activity in arresting the proliferation of undifferentiated cells and
inducing their differentiation to the monocyte thus evidencing use as an anti-
cancer agent and for the treatment of skin diseases such as psoriasis. This
compound also increases both breaking strength and crushing strength of bones
evidencing use in conjunction with bone replacement surgery such as hip and
15 knee replacements.